|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kamisawa T, Wood LD, Itoi T and Takaori K:
Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saad AM, Turk T, Al-Husseini MJ and
Abdel-Rahman O: Trends in pancreatic adenocarcinoma incidence and
mortality in the United States in the last four decades; a
SEER-based study. BMC Cancer. 18:6882018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
de Sousa Cavalcante L and Monteiro G:
Gemcitabine: Metabolism and molecular mechanisms of action,
sensitivity and chemoresistance in pancreatic cancer. Eur J
Pharmacol. 741:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ina S, Hirono S, Noda T and Yamaue H:
Identifying molecular markers for chemosensitivity to gemcitabine
in pancreatic cancer: Increased expression of interferon-stimulated
gene 15 kd is associated with intrinsic chemoresistance. Pancreas.
39:473–485. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Luo W, Yang G, Qiu J, Luan J, Zhang Y, You
L, Feng M, Zhao F, Liu Y, Cao Z, et al: Novel discoveries targeting
gemcitabine-based chemoresistance and new therapies in pancreatic
cancer: How far are we from the destination? Cancer Med.
8:6403–6413. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chiorean EG, Cheung WY, Giordano G, Kim G
and Al-Batran SE: Real-world comparative effectiveness of
nab-paclitaxel plus gemcitabine versus FOLFIRINOX in
advanced pancreatic cancer: A systematic review. Ther Adv Med
Oncol. 11:17588359198503672019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vasan N, Baselga J and Hyman DM: A view on
drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aleksakhina SN, Kashyap A and Imyanitov
EN: Mechanisms of acquired tumor drug resistance. Biochim Biophys
Acta Rev Cancer. 1872:1883102019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mohammad IS, He W and Yin L: Understanding
of human ATP binding cassette superfamily and novel multidrug
resistance modulators to overcome MDR. Biomed Pharmacother.
100:335–348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lowrence RC, Subramaniapillai SG,
Ulaganathan V and Nagarajan S: Tackling drug resistance with efflux
pump inhibitors: From bacteria to cancerous cells. Crit Rev
Microbiol. 45:334–353. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bugde P, Biswas R, Merien F, Lu J, Liu DX,
Chen M, Zhou S and Li Y: The therapeutic potential of targeting ABC
transporters to combat multi-drug resistance. Expert Opin Ther
Targets. 21:511–530. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fletcher JI, Williams RT, Henderson MJ,
Norris MD and Haber M: ABC transporters as mediators of drug
resistance and contributors to cancer cell biology. Drug Resist
Updat. 26:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Adamska A and Falasca M: ATP-binding
cassette transporters in progression and clinical outcome of
pancreatic cancer: What is the way forward? World J Gastroenterol.
24:3222–3238. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Falasca M and Linton KJ: Investigational
ABC transporter inhibitors. Expert Opin Investig Drugs. 21:657–666.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cui H, Zhang AJ, Chen M and Liu JJ: ABC
Transporter inhibitors in reversing multidrug resistance to
chemotherapy. Curr Drug Targets. 16:1356–1371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bates S, Kang M, Meadows B, Bakke S,
Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, et al: A
Phase I study of infusional vinblastine in combination with the
P-glycoprotein antagonist PSC 833 (valspodar). Cancer.
92:1577–1590. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Knuefermann C, Lu Y, Liu B, Jin W, Liang
K, Wu L, Schmidt M, Mills GB, Mendelsohn J and Fan Z:
HER2/PI-3K/Akt activation leads to a multidrug resistance in human
breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang W, Xiao Y, Li S, Zhu X, Meng L, Song
C, Yu C, Jiang N and Liu Y: Synergistic activity of magnolin
combined with B-RAF inhibitor SB590885 in hepatocellular carcinoma
cells via targeting PI3K-AKT/mTOR and ERK MAPK pathway. Am J Transl
Res. 11:3816–3824. 2019.PubMed/NCBI
|
|
21
|
Gao X, Qin T, Mao J, Zhang J, Fan S, Lu Y,
Sun Z, Zhang Q, Song B and Li L: PTENP1/miR-20a/PTEN axis
contributes to breast cancer progression by regulating PTEN via
PI3K/AKT pathway. J Exp Clin Cancer Res. 38:2562019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maira SM, Pecchi S, Huang A, Burger M,
Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, et al:
Identification and characterization of NVP-BKM120, an orally
available pan-class I PI3-kinase inhibitor. Mol Cancer Ther.
11:317–328. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirai H, Sootome H, Nakatsuru Y, Miyama K,
Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS and
Kotani H: MK-2206, an allosteric Akt inhibitor, enhances antitumor
efficacy by standard chemotherapeutic agents or molecular targeted
drugs in vitro and in vivo. Mol Cancer Ther. 9:1956–1967. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ghobrial IM, Witzig TE and Adjei AA:
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin.
55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Banerjee S, Wang Z, Kong D and Sarkar FH:
3,3-Diindolylmethane enhances chemosensitivity of multiple
chemotherapeutic agents in pancreatic cancer. Cancer Res.
69:5592–5600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bharti AC and Aggarwal BB: Nuclear
factor-kappa B and cancer: Its role in prevention and therapy.
Biochem Pharmacol. 64:883–888. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ng SS, Tsao MS, Nicklee T and Hedley DW:
Wortmannin inhibits pkb/akt phosphorylation and promotes
gemcitabine antitumor activity in orthotopic human pancreatic
cancer xenografts in immunodeficient mice. Clin Cancer Res.
7:3269–3275. 2001.PubMed/NCBI
|
|
28
|
Gilles ME, Maione F, Cossutta M,
Carpentier G, Caruana L, Di Maria S, Houppe C, Destouches D,
Shchors K, Prochasson C, et al: Nucleolin targeting impairs the
progression of pancreatic cancer and promotes the normalization of
tumor vasculature. Cancer Res. 76:7181–7193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yoon Y, Lim JW, Kim J, Kim Y and Chun KH:
Discovery of ursolic acid prodrug (NX-201): Pharmacokinetics and in
vivo antitumor effects in PANC-1 pancreatic cancer. Bioorg Med Chem
Lett. 26:5524–5527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gottesman MM and Ambudkar SV: Overview:
ABC transporters and human disease. J Bioenerg Biomembr.
33:453–458. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lage H: An overview of cancer multidrug
resistance: A still unsolved problem. Cell Mol Life Sci.
65:3145–3167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tutt AN, Lord CJ, McCabe N, Farmer H,
Turner N, Martin NM, Jackson SP, Smith GC and Ashworth A:
Exploiting the DNA repair defect in BRCA mutant cells in the design
of new therapeutic strategies for cancer. Cold Spring Harb Symp
Quant Biol. 70:139–148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu H, Chen S and Cao P: Synergistic
bactericidal effects and mechanisms of low intensity ultrasound and
antibiotics against bacteria: A review. Ultrason Sonochem.
19:377–382. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu T, Hu K, Bai J and Wang Z: Reversal of
adriamycin resistance in ovarian carcinoma cell line by combination
of verapamil and low-level ultrasound. Ultrason Sonochem. 10:37–40.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang S, Wang P, Wang X, Su X and Liu Q:
Activation of microbubbles by low-level therapeutic ultrasound
enhances the antitumor effects of doxorubicin. Eur Radiol.
24:2739–2753. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hassan MA, Furusawa Y, Minemura M,
Rapoport N, Sugiyama T and Kondo T: Ultrasound-induced new cellular
mechanism involved in drug resistance. PLoS One. 7:e482912012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu Y, Cho CW, Yan X, Henthorn TK,
Lillehei KO, Cobb WN and Ng KY: Ultrasound-Induced hyperthermia
increases cellular uptake and cytotoxicity of P-glycoprotein
substrates in multi-drug resistant cells. Pharm Res. 18:1255–1261.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ning Z, Zhu Z, Wang H, Zhang C, Xu L,
Zhuang L, Yan X, Wang D, Wang P and Meng Z: High-intensity focused
ultrasound enhances the effect of bufalin by inducing apoptosis in
pancreatic cancer cells. OncoTargets Ther. 12:1161–1170. 2019.
View Article : Google Scholar
|
|
39
|
Liu L, Chang S, Sun J, Zhu S, Yin M, Zhu
Y, Wang Z and Xu RX: Ultrasound-mediated destruction of paclitaxel
and oxygen loaded lipid microbubbles for combination therapy in
ovarian cancer xenografts. Cancer Lett. 361:147–154. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang C, Huang S, Li H, Li X, Li B, Zhong
L, Wang J, Zou M, He X, Zheng H, et al: The effects of ultrasound
exposure on P-glycoprotein-mediated multidrug resistance in vitro
and in vivo. J Exp Clin Cancer Res. 37:2322018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wu Y, Liu X, Qin Z, Hu L and Wang X:
Low-frequency ultrasound enhances chemotherapy sensitivity and
induces autophagy in PTX-resistant PC-3 cells via the endoplasmic
reticulum stress-mediated PI3K/Akt/mTOR signaling pathway.
OncoTargets Ther. 11:5621–5630. 2018. View Article : Google Scholar
|
|
42
|
Sun Y, Li Q, Xu Y, Pu C, Zhao L, Guo Z,
Ding X and Jin X: Study of the mechanisms underlying the reversal
of multidrug resistance of human neuroblastoma multidrug-resistant
cell line SK-N-SH/MDR1 by low-intensity pulsed ultrasound. Oncol
Rep. 29:1939–1945. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
He Y, Bi Y, Ji XJ and Wei G: Increased
efficiency of testicular tumor chemotherapy by ultrasound
microbubble-mediated targeted transfection of siMDR1. Oncol Rep.
34:2311–2318. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nieth C and Lage H: Induction of the
ABC-transporters Mdr1/P-gp (Abcb1), mrpl (Abcc1), and bcrp (Abcg2)
during establishment of multidrug resistance following exposure to
mitoxantrone. J Chemother. 17:215–223. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim MP and Gallick GE: Gemcitabine
resistance in pancreatic cancer: Picking the key players. Clin
Cancer Res. 14:1284–1285. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Andersson R, Aho U, Nilsson BI, Peters GJ,
Pastor-Anglada M, Rasch W and Sandvold ML: Gemcitabine
chemoresistance in pancreatic cancer: Molecular mechanisms and
potential solutions. Scand J Gastroenterol. 44:782–786. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang PF, Li KS, Shen YH, Gao PT, Dong ZR,
Cai JB, Zhang C, Huang XY, Tian MX, Hu ZQ, et al: Galectin-1
induces hepatocellular carcinoma EMT and sorafenib resistance by
activating FAK/PI3K/AKT signaling. Cell Death Dis. 7:e22012016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liang F, Ren C, Wang J, Wang S, Yang L,
Han X, Chen Y, Tong G and Yang G: The crosstalk between STAT3 and
p53/RAS signaling controls cancer cell metastasis and cisplatin
resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT
and autophagy. Oncogenesis. 8:592019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
To KK and Fu LW: CUDC-907, a dual HDAC and
PI3K inhibitor, reverses platinum drug resistance. Invest New
Drugs. 36:10–19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ma JX, Sun YL, Yu Y, Zhang J, Wu HY and Yu
XF: Triptolide enhances the sensitivity of pancreatic cancer PANC-1
cells to gemcitabine by inhibiting TLR4/NF-κB signaling. Am J
Transl Res. 11:3750–3760. 2019.PubMed/NCBI
|
|
51
|
Mulero MC, Wang VY, Huxford T and Ghosh G:
Genome reading by the NF-κB transcription factors. Nucleic Acids
Res. 47:9967–9989. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Solt LA and May MJ: The IkappaB kinase
complex: Master regulator of NF-kappaB signaling. Immunol Res.
42:3–18. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hien TT, Kim HG, Han EH, Kang KW and Jeong
HG: Molecular mechanism of suppression of MDR1 by puerarin from
Pueraria lobata via NF-kappaB pathway and cAMP-responsive element
transcriptional activity-dependent up-regulation of AMP-activated
protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res.
54:918–928. 2010. View Article : Google Scholar : PubMed/NCBI
|
